The study found the interaction between IL-10 and COMT gene polymorphism in cognitive function in patients with schizophrenia

Cognitive impairment is one of the core symptoms of schizophrenia, and dopamine and inflammatory systems have been shown to play an important role in cognitive impairment of schizophrenia, and there is growing evidence that the two systems interact.
on the other hand, most immune cells express dopamine bodies, which means that dopamine can affect almost all immune cells and promote the secretion of cytokine factors.
other hand, cytokines can also affect the synthesis, packaging and release of dopamine, regulating the body's dopamine levels.
, however, there is still limited research on the interaction between the two systems.
gisphonol-o-methyl transferase (COMT) is a dopamine degradation enzyme, is one of the main regulatory pathways of dopamine in the brain, especially in the forehead cortline region, so its function is considered to be closely related to cognitive function.
COMT has a common single base polymorphism (SNP) bit Val158Met (rs4680) in the population, which causes two types of COMT proteins, Val type proline or Met type of methionine in the 158th amino acid.
studies have shown that people who carry Met have higher levels of dopamine, show better cognitive abilities, have a lower risk of developing schizophrenia, and have better treatment outcomes.
10 (IL-10) is a class of anti-inflammatory cytokines that inhibit the body's inflammatory response and is considered a protective factor.
IL-10 also has a common SNP bit -592A/C (rs1800872).
previous studies have shown that individuals with type A points have higher levels of IL-10, so they have lower inflammatory levels and a lower risk of developing schizophrenia, which can lead to better cognitive function even with the disease.
of these two genetic points are associated with cognitive function and schizophrenia, but no studies have yet taken into account the effects of these two genetic points from different systems on cognitive function in patients with schizophrenia and healthy populations.
, Wang Jies, an assistant researcher in the Mental Health Key Laboratory of the Institute of Psychology of the Chinese Academy of Sciences, conducted a targeted study.
the study recruited 244 patients with chronic schizophrenia and 396 healthy controls to test the genetic polymorphisms of COMT Val158Met and IL-10-592A/C, and to assess their cognitive abilities in many areas using the Neuropsychiast Scale (RBANS).
study found that the above two genetic points interact on the effects of multiple cognitive functions in patients with schizophrenia and healthy people, and the direction of their action is interdependent, especially in patients with schizophrenia.
, for example, previous studies have suggested that carriers of the IL-10 A gene have better cognitive function, but the study found that this phenomenon exists only in COMT Val carriers, while carriers of the IL-10 A gene in COMT Met carriers actually have worse cognitive function.
's effects on COMT are similar, for example, Met-type carriers, traditionally thought to have higher cognitive function, actually have better cognitive function only if they have the IL-10 C gene at the same time;
may be due to the fact that both dopamine and inflammatory systems play an important role in cognitive function, not the balance of the system rather than the level.
is not dopamine, the lower the inflammatory level, the better cognitive function.
studies have shown that high dopamine levels and low inflammatory levels can impair an individual's cognitive function.
because inflammatory and dopamine systems can regulate each other, the effects of the two genetic points in the study on cognitive function showed interdependence and interaction.
the study found that IL-10 and COMT gene polymorphism interact in cognitive function, providing examples of cognitive defects in multi-system synergy in schizophrenia, which is important for further research and guidance on drug use.
research has been supported by the National Natural Science Foundation of China and the Key Laboratory of Mental Health of the Chinese Academy of Sciences.
study was published in the Journal of Psychiatry Research.
Wang Jies is the first author of the thesis and Zhang Xiangyang is the first author of the paper.
()